Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Starpharma Holdings Limited ( (AU:SPL) ) just unveiled an update.
Starpharma Holdings Limited has notified the market that 381,810 performance rights (ASX code: SPLAK) lapsed on 31 December 2025 after the conditions attached to those rights were not met or became incapable of being satisfied. The cessation of these conditional securities slightly reduces the company’s potential future share dilution and reflects the non-fulfilment of specified performance hurdles, but does not directly affect the number of ordinary shares currently on issue.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an Australian-listed biotechnology company (ASX: SPL) focused on developing innovative pharmaceutical and life science products, including drug delivery and antiviral technologies, typically targeting global healthcare markets.
Average Trading Volume: 707,581
Technical Sentiment Signal: Hold
Current Market Cap: A$146.4M
Find detailed analytics on SPL stock on TipRanks’ Stock Analysis page.